Amphastar Pharmaceuticals receives FDA approval for Albuterol Sulfate Inhalation Aerosol (AMP-008).

Amphastar Pharmaceuticals receives FDA approval for its ANDA of Albuterol Sulfate Inhalation Aerosol (AMP-008), treating/preventing bronchospasm in patients 4+ with reversible obstructive airway disease. The FDA considers it bioequivalent to Teva Respiratory's ProAir® HFA. Amphastar plans to launch in Q3 2024, targeting products with combined market sizes of over $10.4B.

May 22, 2024
3 Articles